Similar results were provided by phase II trials on treatment with dabrafenib of the rare BRAF-mutated non-small-cell lung cancers (NSCLC) in which the BRAF-inhibitor alone gave disappointing results, whereas combination with the MEK-inhibitor Tramentib produced some benefit in terms of overall response rate [57, 58]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.